Clinical Audit On Management Of Congenital Heart Disease In ACUH

Status Not yet recruiting

Clinical Trial Summary

Congenital Heart Disease (CHD) is the most common birth defect in the United States, affecting approximately 0.8% of live births. Improved treatment strategies and interventions have increased survival such that 85% to 90% of affected children are expected to live well into adulthood, thereby causing a demographic shift in which adults now outnumber children with CHD, and more people with complex CHD are living longer.

Clinical Trial Description

CHD may be defined as an anatomic malformation of the heart or great vessels which occurs during intrauterine development, irrespective of the age at presentation. The cause of most congenital heart defects is still unknown. Many cases of congenital heart disease are multifactorial and result from a combination of genetic predisposition and an environmental stimulus. A small percentage of congenital heart lesions are related to known chromosomal abnormalities, in particular, trisomy 21, 13, and 18 and Turner syndrome. Of all cases of congenital heart disease, 2-4% are associated with known environmental or adverse maternal conditions and teratogenic influences, including maternal diabetes mellitus, phenylketonuria, systemic lupus erythematosus or congenital rubella syndrome; and maternal ingestion of drugs (lithium, ethanol, warfarin, antimetabolites, vitamin A derivatives, anticonvulsant agents). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03850223
Study type	Observational
Source	Assiut University
Contact	Mostafa Shafeek Khalaf, Professor
Phone	+201112110096
Email	mostafa.tawfeek1@med.au.edu.eg
Status	Not yet recruiting
Phase
Start date	March 1, 2020
Completion date	December 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05654272` - Development of CIRC Technologies
Recruiting	`NCT04992793` - Paediatric Brain Injury Following Cardiac Interventions
Recruiting	`NCT05213598` - Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Completed	`NCT04136379` - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed	`NCT04814888` - 3D Airway Model for Pediatric Patients
Recruiting	`NCT04920643` - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery	N/A
Completed	`NCT05934578` - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training	N/A
Recruiting	`NCT06041685` - Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia	N/A
Recruiting	`NCT05902013` - Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation	N/A
Not yet recruiting	`NCT05687292` - Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
Not yet recruiting	`NCT05524324` - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT	N/A
Completed	`NCT02746029` - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed	`NCT02537392` - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease	N/A
Completed	`NCT03119090` - Fontan Imaging Biomarkers (FIB) Study
Recruiting	`NCT02258724` - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed	`NCT01966237` - Milrinone Pharmacokinetics and Acute Kidney Injury
Terminated	`NCT02046135` - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery	Phase 2
Recruiting	`NCT01184404` - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery	N/A
Completed	`NCT01548950` - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension	N/A
Completed	`NCT01178710` - Effect of Simvastatin on Cardiac Function	N/A